Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer.
Cristina MüllerAviral SinghChristoph A UmbrichtHarshad R KulkarniKarl JohnstonMartina BenešováStefan SenftlebenDirk MüllerChristiaan VermeulenRoger SchibliUlli KösterNicholas P van der MeulenRichard P BaumPublished in: EJNMMI research (2019)
The results of this study demonstrate the successful preparation and preclinical testing of 152Tb-PSMA-617 and its first application in a patient with mCRPC. This work could pave the way towards clinical application of other Tb radionuclides in the near future, most importantly 161Tb, which has promising decay characteristics for an effective treatment of mCRPC patients.
Keyphrases
- pet ct
- mycobacterium tuberculosis
- prostate cancer
- positron emission tomography
- end stage renal disease
- endothelial cells
- ejection fraction
- newly diagnosed
- cell therapy
- high resolution
- peritoneal dialysis
- prognostic factors
- radical prostatectomy
- case report
- pet imaging
- stem cells
- computed tomography
- patient reported outcomes
- pluripotent stem cells